



SPIDIA-RNA: First External Quality Assessment for the preanalytical phase of blod samples used for RNA based analyses





¹University of Florence, Dept. Biochemical Experimental & Clinical Sciences, Italy; ²QIAGEN GmbH, Hilden, Germany; ³Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁴Charles University, Faculty of Medicine, Pilsen, Czech Republic; ⁵TATAA Biocenter AB, Gothenburg, Sweden


<u>Malentacchi F.¹, Simi L.¹, Orlando C.¹, Wyrich R.², Günther K.², Hartmann C.², Verderio P.³, Pizzamiglio S.³,</u>

Ciniselli C.³, Tichopad A.⁴, Kubista M.⁵, Gelmini S.¹, Pazzagli M.¹

The diagnostic use of in vitro molecular assays can be limited by the lack of guidelines for collection, handling, stabilisation and storage of patient specimens. One of the goal of the EC funded project SPIDIA (Standardisation and improvement of preanalytical procedures for in vitro diagnostics, www.spidia.eu) was the implementation of a pan-European External Quality Assessment (EQA).


METHODS


102 laboratories were recruited fro the EQA by the European federation of Laboratory Medicine (EFLM) support.





SPIDIA-UNIFI collected the blood from 7 donors, pooled and sent the same samples to all participants. Participants received 2 blood samples with or without stabiliser (PAXgene Blood RNA tube® or K2EDTA, they chose the tubes during the enrolment) and performed RNA extraction following their own procedure, a questionnaire and result form to collect the data. The RNAs were sent back to SPIDIA-UNIFI in dry ice. **SPIDIA-UNIFI** performed the "RNA QUALITY PARAMETERS" analysis as follow:

- Yield & purity
- (by spectrophotometer- Nanodrop)
- Integrity (by Agilent Bioanalyzer 2100, RIN RNA Integrity Number)









- mRNA stability

(absolute quantification by qPCR of IL1 β , IL8, c-Fos and GAPDH gene expression)

- qPCR interferences

(by Kineret® software – analysis of qPCR kinetics)

...and developed a REPORT for the participants containing the performance and the comparison of each RNA quality parameter among the other laboratories (consensus mean).

RESULTS

Questionnaire results

research lab university lab

bacteriology

coagulation

haematolog

Questions		% of labs		🌒 s	PIDIA		SPIDIA	- RNA	A: Labora	tory re	eport	
1 - In which tube do you usually	K ₂ EDTA	66%						Lab	ID: L235			
perform blood collection?	NaCitrate	2%	A. Purity and Quantity of RNA A and RNA B A.1 Spectrophotometric data provided by your lab									
	LiEparine	1%	Γ	sample	280nm	280nm	320nm	Purity	Quantity (ng/µi blood)	Dilution factor	Extraction vol. (ul)	Elui vol.
	PAXgene blood RNA tube	23%		RNA A RNA B	5.802 5.002	2.997 2.578		1.940 1.940	5.802 5.003	1	2000 2000	5. 5.

REPORT distribution of each RNA quality parameters and sigle parameter/laboratory performance	REPORT	distribution	of each RNA	quality p	parameters and	sigle paramete	er/laboratory	performance
---	--------	--------------	-------------	-----------	----------------	----------------	---------------	-------------


0


RNA A (N=91)

In control


				• • •	
100			SPIDIA	SPIDIA – RNA: Laboratory report	
				Lab ID: L235	
			B. Integrity of RN/	A A and RNA B	
		1	B.1 Your lab (•) versi	us overall distribution – RIN number	
Jution ol. (ul)	Buffer		In the figures the blue line re	epresents the Action Limit (AL) and the gray line represents the Warning Limit (V	NL).
50	RNase free water				
50	RNese free water		10 -		

🌒 SPIDIA	SPIDIA – F	RNA: Laborat	ory report	01			
E. Summary	I	Lab ID: L235			Overall perfo	rmanc	es
	F	Performance	Missing	Comments			
RNA A - Purity	In control						
RNA B - Purity	In control				Cotocorios		0
RNA A - Quantity	In control				Categories	N	





INA A - Integrity			out of control		
INA B - Integrity			out of collabor	missing	
RNA A - C-FOS quant	in control			meeng	
RNA A - GAPDH quant	in concor		out of control		
RNA A - IL 1b quant	+	warning	out of control		
	1	warning			
RNA A - IL8 quant	In control				
RNA B - C-FOS quant	in control				
RNA B - GAPDH quant		warning			
RNA B – IL 1b quant	In control				
RNA B – ILS quant	In control				
RNA A - C-FOS Interferences	In control				
RNA A - GAPDH Interferences				missing	
RNA A – IL 1b Interferences	In control				
RNA A – IL8 Interferences	in control				
RNA B - C-FOS Interferences	in control				
RNA B - GAPDH Interferences				missing	
RNA B - IL1b Interferences	In control				
RNA B - ILS Interferences	In control				




		, .
II in control or warning	24	25.81
erformance		
nly one out of control	27	29.03
nd/or missing		
erformance		
ther	42	45.16
otal	93	100


Categories:

all in control or warning performance: labs with all performances "in control" or "warning"; only one out of control and/or missing performance: labs with only one "out of control" or labs with only one "missing" or labs with one "out of control" and one "missing" performance;

other: labs with two or more "out of control" and/or two or more "missing" performance. Also, labs with two or more "missing" and one "out of control" and viceversa.

INFLUENCE OF QUALITY PARAMETER ON GENE EXPRESSION: RNA integrity (RIN) and gene expression (GAPDH)





GAPDH expression in RNA A and RIN variable dichotomized according to the cut-off value of 5 (N lab = 20 for RIN 6 5; N lab = 57 for RIN > 5; Kruskal–Wallis test, p < 0.0001).

The median value of RIN and PURITY are closed to expected high quality RNA. No drammatic gene expression changing within 72h of blood storage. Few qPCR interferences (none for GAPDH). RIN value (cut off = 5) influences specific gene expression.

CONCLUSION

The results of this EQA will be used to to enhance a second Pan-European EQA.

The results of both EQAs will be the basis for the implementation of evidence-based guidelines for blood sample managing to obtain good quality RNA sample

SPIDIA-RNA: first external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. Pazzagli M, Malentacchi F, Simi L, Orlando C, Wyrich R, Günther K, Hartmann CC, Verderio P, Pizzamiglio S, Ciniselli CM, Tichopad A, Kubista M, Gelmini S. Methods. 2013 Jan; 59(1): 20-31.